Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: SpectraCure AB

Market Cap 25.16M 2.59M 2.27M 2.1M 1.96M 3.68M 245M 3.74M 9.74M 120M 9.72M 9.51M 418M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 14.43M 1.48M 1.3M 1.2M 1.12M 2.11M 141M 2.14M 5.58M 68.99M 5.57M 5.45M 240M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-1.81%
1 week-5.87%
Current month-69.07%
1 month-52.42%
3 months-50.63%
6 months-72.77%
Current year-72.21%
1 week 0.04
Extreme 0.0403
0.05
1 month 0.04
Extreme 0.0403
0.17
Current year 0.04
Extreme 0.0403
0.17
1 year 0.04
Extreme 0.0403
0.32
3 years 0.04
Extreme 0.0403
6.43
5 years 0.04
Extreme 0.0403
13.19
10 years 0.04
Extreme 0.0403
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
26/05/23Buy

Chairman

25,000 0.0257%
30/08/22Buy

Director

25,000 0.0257%
09/07/22Buy

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%-5.87%-82.68%-99.30% 2.62M
-1.53%-2.34%+58.29%+52.65% 1.56B
-2.92%-8.90%-39.82%-42.67% 307M
-3.11%-4.39%-2.85%-51.12% 54.7M
Average -2.34%-3.99%-16.76%-35.11% 479.96M
Weighted average by Cap. -1.80%-2.33%+40.68%+34.25%

Financials

2024 2025
Net sales - -
Net income -23M -2.37M -2.08M -1.92M -1.79M -3.36M -224M -3.42M -8.9M -110M -8.88M -8.69M -382M -56.08M -5.77M -5.07M -4.67M -4.37M -8.19M -547M -8.33M -21.71M -268M -21.66M -21.19M -932M
Net Debt -13.13M -1.35M -1.19M -1.09M -1.02M -1.92M -128M -1.95M -5.08M -62.78M -5.07M -4.96M -218M -10.74M -1.1M -970K -894K -837K -1.57M -105M -1.59M -4.16M -51.34M -4.15M -4.06M -178M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
24/06/26 SEK 0.0433 -1.81% 1,361,199
22/06/26 SEK 0.0441 -10.91% 3,245,919
18/06/26 SEK 0.0495 +5.32% 876,611
17/06/26 SEK 0.0470 +2.17% 4,047,880
16/06/26 SEK 0.0460 -0.22% 2,014,386
  1. Stock Market
  2. Stocks
  3. SPEC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!